Dr. Robin Falkov and Dr. Fernando Bassail discuss the FDA-approved Neobryxol/Bryomixol (US brand name is Bryomed) treatment that has enabled former cancer patients to recover from their illness.
PharmaTech manufactures and owns the rights to the Neobryxol/Bryomixol product line. Dr. Bassail serves as Vice President of PharmaTech while his clinical colleague, Dr. Cesar Bertacchinij , serves as President.
Dr. Bassail commutes between his primary care facility in El Salvador (Hospital de Diagnóstico) and offices in Orange County, California.
Click here to read about Dr. Bassail’s last appearance on the radio program on April 8.